Brassicasterol inhibits hepatitis B virus-associated hepatocellular carcinoma development via suppression of AKT signaling pathway.

ABSTRACT:

Background

Hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) does not respond well to current treatment options like sorafenib, and there is an urgent need for developing therapeutical strategies for HBV + HCC. Brassicasterol has previously shown anti-cancer and anti-viral activities, however, its value against HBV + HCC remains to be explored.

Methods

The inhibitory effect of brassicasterol and sorafenib was evaluated on HBV + HCC cell lines and xenograft mouse model. The cytotoxicity of brassicasterol on normal liver cells were measured by LDH assay. AKT agonist was used to identify the targeted signaling pathway by brassicasterol.

Results

Brassicasterol induced HBV + HCC cell death in a both dose-dependent and time-dependent manner, and such inhibit

SUBMITTER: Zeng J 

PROVIDER: S-EPMC10116783 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature